Objective. To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)-related interstitial lung disease (ILD).
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Objective. To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)-related interstitial lung disease (ILD).
Methods. We included participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II. SLS I randomized participants to receive either oral cyclophosphamide (CYC) or placebo for 1 year, while SLS II randomized participants to receive either MMF for 2 years or oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and SLS II were nearly identical. The primary outcome was % predicted forced vital capacity (FVC), and key secondary outcomes included % predicted diffusing capacity for carbon monoxide (DLCO), the modified Rodnan skin thickness score (MRSS), and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years.
Results. At baseline, the MMF-treated group in SLS II (n 5 69) and the placebo-treated group in SLS I (n 5 79) had similar percentages of men and women and similar disease duration, SSc subtype, extent of skin disease, and % predicted FVC. MMF-treated patients in SLS II were slightly older (mean 6 SD age 52.6 6 9.7 years versus 48.1 6 12.4 years; P 5 0.0152) and had higher % predicted DLCO (mean 6 SD 54.0 6 11.1 versus 46.2 6 13.3; P 5 0.0002) than placebo-treated patients in SLS I. After adjustment for baseline disease severity, treatment with MMF in comparison with placebo was associated with improved % predicted FVC (P < 0.0001), % predicted DLCO (P < 0.0001), MRSS (P < 0.0001), and dyspnea (P 5 0.0112) over 2 years.
Conclusion. Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc-related ILD.
emerged as an alternative treatment for SSc-related ILD (5) . Uncontrolled studies have demonstrated that MMF may prevent progression of SSc-related ILD (6) (7) (8) (9) (10) (11) (12) .
To further explore the safety and efficacy of MMF in SSc-related ILD, Tashkin and colleagues designed Scleroderma Lung Study (SLS) II to directly compare CYC with MMF for the treatment of SSc-related ILD (13) . The study demonstrated that the majority of participants in the MMF arm (72%) showed improvements in % predicted forced vital capacity (FVC) (13) . However, as the study design lacked a placebo arm, it has been difficult to interpret the absolute magnitude of the treatment effect for MMF when compared to the natural history of SSc-related ILD. A proportion of patients with SSc-related ILD exhibit intrinsically stable ILD that fails to progress even in the absence of treatment (14) .
To address this shortcoming, the present study compared outcomes for patients assigned to the MMF arm of SLS II with outcomes for patients assigned to the placebo arm of SLS I. The primary objective was to determine whether patients assigned to receive MMF experienced an improvement in % predicted FVC over 24 months compared with patients assigned to receive placebo. The study also aimed to compare secondary efficacy outcomes and the safety profiles for patients in these 2 groups.
PATIENTS AND METHODS
Study participants. All participants enrolled in the MMF arm of SLS II (13) and the placebo arm of SLS I (3) were included in this analysis. Participating centers and investigators were similar for both trials. Eligibility criteria for both studies were also similar. Common inclusion criteria were age $18 years, duration of disease #7 years from onset of the first nonRaynaud's phenomenon symptom of SSc, FVC 40-85% predicted (SLS I) or 40-80% predicted (SLS II), hemoglobinadjusted single-breath diffusing capacity for carbon monoxide (DLCO) $40% predicted (or 30-39% predicted if no evidence of clinically significant pulmonary hypertension), and evidence of any ground glass opacity (i.e., hazy parenchymal opacity) on highresolution computed tomography (HRCT) of the chest in the presence or absence of reticular opacity or architectural distortion, as an indication of "active" disease. MMF and matching placebo were supplied at no charge through Drug Supply Grant CEL539 from Hoffmann-La Roche/Genentech.
The only difference between SLS I and SLS II entry criteria related to bronchoscopy. In SLS I, patients were encouraged to undergo a screening bronchoscopy and considered eligible if they had $3% neutrophils and/or $2% eosinophils in bronchoalveolar lavage fluid even if they had an HRCT scan that did not show any ground glass opacity. Sixteen of the 162 randomized participants (9.9%) in SLS I were included based on these criteria. Although they did not have ground glass opacity, all of these patients did exhibit evidence of fibrosis on HRCT. Bronchoscopy was not performed in SLS II, and all patients were required to have ground glass opacity on HRCT. Exclusion criteria for both studies were nearly identical (3, 13) . SLS I and SLS II study design. SLS I consisted of 162 participants randomized between September 2000 and January 2004 and assigned to receive either oral CYC (titrated to 2.0 mg/kg once daily) or matching placebo for 1 year followed by an additional year of observation while not receiving treatment, as previously reported (15) . In SLS II, 142 patients were randomized between September 2009 and December 2012 and assigned to receive either MMF (titrated as tolerated to 3.0 gm/day in divided doses) for 2 years or oral CYC (titrated as tolerated to 2 mg/kg once daily) for 1 year followed by an additional year receiving placebo, using a double-dummy design to maintain the blinding (13) .
SLS I and SLS II assessment measurement. Baseline measurements included the following physiologic variables: spirometry (FVC, forced expiratory volume in 1 second), lung volumes (functional residual capacity, residual volume, and total lung capacity by whole-body plethysmography or helium dilution), and DLCO and DLCO corrected for alveolar volume. The FVC (primary SLS I/II end point) and DLCO (secondary SLS I/II end point) were measured every 3 months during the trials. Dyspnea was assessed using the Baseline Dyspnea Index (BDI) at baseline and using the Transition Dyspnea Index (TDI) every 3 months thereafter for SLS I and every 6 months thereafter for SLS II (16, 17) . In SLS I, an interview-administered paper version of the BDI/TDI was used (16) , while in SLS II a selfadministered computer-assisted version of the BDI/TDI was used (17) . The modified Rodnan skin thickness score (MRSS) (18) was used to assess cutaneous sclerosis. The MRSS was obtained every 3 months in SLS II and every 6 months in SLS I.
HRCT thoracic imaging was obtained at baseline and at 24 months in SLS II and at baseline and at 12 months in SLS I. Both studies used similar HRCT acquisition and analysis methods (19) , except that in SLS I nonvolumetric CT scans of 1-2-mm slice thickness were acquired at 10-mm increments, while in SLS II volumetric CT scans of 1-1.5-mm slice thickness were acquired contiguously. For both studies, scans were reconstructed with sharp or manufacturer-recommended overenhancing filters. After semiautomated lung segmentation, the images were entered into a quantitative image workstation to produce quantitative scores automatically as described previously (20) . For the present study, we report the quantitative lung fibrosis score, which represents the percentage of counts with reticular opacity with architectural distortion, and the quantitative ILD (QILD) score, which represents the sum of all scores classified as abnormal, including scores for fibrosis, ground glass opacity, and honeycombing, defined as clustered air-filled cysts with dense walls. In both studies, scores were summed using the same methods both for the whole lung (including both lungs) and for the zone of maximal involvement.
Statistical analysis. Baseline characteristics. Summary statistics were generated for baseline characteristics of the 2 cohorts. Group comparisons were performed using a 2-sample ttest, a Wilcoxon rank sum test, and a chi-square test.
Primary outcome of FVC (% predicted). An intent-totreat principle was applied to all analyses using an inferential joint model consisting of a mixed-effects model for longitudinal outcomes and a survival model to handle nonignorable missing data due to study dropout, treatment failure, or death (i.e., likely related to disease or treatment and therefore not random) (21, 22 ). The joint model was used as our primary inferential approach because it can provide unbiased and efficient estimates when there are nonignorable missing data in the outcomes due to 1452 VOLKMANN ET AL dropouts, treatment failures, and deaths. The complete-case analysis was not believed to be a valid approach in this scenario since it assumes data are missing completely at random. Consistent with the intent-to-treat principle, those for whom treatment had failed and others who withdrew prematurely from the doubleblind treatment phase were encouraged to return for outcome monitoring up until 24 months for both studies. Repeated measurements of % predicted FVC were characterized by a linear mixed-effects submodel in the joint model, and intrasubject data correlation among multiple measurements over time was accounted for by random intercept and random time trend. Fixed effects were prespecified covariates for the primary outcome including baseline % predicted FVC, baseline whole lung QILD score, a time trend, treatment assignment, treatment assignmenttime trend interactions, and treatment assignment-QILD score interaction. The time trend was modeled by linear splines with knots at 12 and 21 months. The location of knots was determined by preliminary examination of the data using descriptive statistics. Treatment assignment was coded as a binary variable with placebo as the reference by convention. Thus, the model estimates 3 piecewise linear trends for the placebo group at 3-12 months, 12-21 months, and 21-24 months as well as change in these time trends in the MMF group when compared to placebo.
Secondary outcomes of DLCO (% predicted), TDI, MRSS, and safety. Secondary efficacy end points were also analyzed using a joint model with no adjustment for multiple comparisons. For safety analyses, descriptive statistics were used to compare the incidence of adverse events (AEs) and serious AEs (SAEs) between treatment arms. The definitions of specific AEs (leukopenia, anemia, etc.) were identical between SLS I and SLS II (3, 13) .
All tests were 2-sided. Group comparisons of baseline characteristics were performed using SAS 9.4 (SAS Institute). The joint model was implemented in C, which calls functions in the GNU Scientific Library (http://www.gnu.org/software/gsl).
RESULTS

Baseline characteristics of the study patients.
Patients assigned to MMF in SLS II and placebo in SLS I exhibited similar baseline demographic features except for a slight difference in age ( Table 1 ). The extent of lung disease, as measured by % predicted FVC, and skin involvement, as measured by the MRSS, were also similar. Patients assigned to placebo had a lower % predicted DLCO and more extensive QILD than those in the MMF arm. Patients assigned to placebo reported more dyspnea at baseline than those assigned to MMF, although, as mentioned above, different versions of the BDI were used in SLS I and SLS II. Disposition of the study participants. In SLS II, 20 patients (29.0%) in the MMF arm prematurely stopped study drug treatment (due to 1 death, no treatment failures, and 19 withdrawals for other reasons) over 24 months. An additional 4 deaths in the MMF arm occurred in subjects who had already withdrawn for other reasons. In SLS I, during the initial 12 months, 24 patients (30.4%) in the placebo arm prematurely stopped study drug treatment (due to 3 deaths, 5 treatment failures, and 16 withdrawals for other reasons). Of the 55 patients in the placebo arm who remained at the conclusion of the 12-month treatment period, 45 completed visits up to and including the 24-month visit. An additional 11 patients in the placebo arm returned for the 24-month visit after having withdrawn or after treatment had failed at earlier time points in the study. Among the 56 patients in the placebo arm who were followed up for the entire 24 months, an additional 10 withdrew from the study during the second year of follow-up (due to 1 death, 3 treatment failures, and 6 withdrawals from the study) (for patient disposition details, see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40114/abstract).
Use of potential disease-modifying therapy in the placebo arm. Of the 56 patients in the placebo arm who were followed up during year 2 of SLS I, 14 began treatment with immunosuppressive agents during this year of observation while not receiving the study drug. Therapies included prednisone at .10 mg daily (mean dose 11.6 mg daily) in 12 patients and oral CYC (mean dose 72.5 mg daily) in 2 patients. No patients received MMF or azathioprine during this time. Our previous study found that neither prednisone nor oral CYC had an independent effect on any of the outcome measures at 24 months in SLS I (15) .
Association of MMF treatment with improved course of FVC. After controlling for baseline % predicted FVC and baseline whole lung QILD score, treatment with MMF was associated with improved % predicted FVC over 24 months (Table 2 and Figure 1 ). The test of the overall treatment group effect for the entire model was highly significant (P , 0.0001). From 3 to 12 months, patients in the MMF arm experienced significant improvement in % predicted FVC compared with those in the placebo arm ( Figure  1 ). There was continued improvement in % predicted FVC from 12 to 24 months in the MMF arm. In contrast, in the placebo arm, there was a significant decline in % predicted FVC from 3 to 12 months, with subsequent improvement from 12 to 21 months. From 12 to 21 months and from 21 to 24 months, there was no significant difference in % predicted FVC between the 2 groups (Table 2 and Figure 1) ; however, as depicted in Supplementary Figures 2 and 3 (http:// onlinelibrary.wiley.com/doi/10.1002/art.40114/abstract), substantially more patients assigned to MMF in SLS II experienced an improvement in FVC at both 12 and 24 months compared with patients assigned to placebo.
Using the intent-to-treat population, 64.4% and 71.7% of MMF-treated patients had any improvement in % predicted FVC at 12 and 24 months, respectively, and the majority of patients who experienced improvement in % predicted FVC at 24 months had an absolute improvement of .5% (Supplementary Figures 2 and 3) . Among those who completed the study, the percentage of MMF-treated patients who had any improvement in % predicted FVC at 24 months was even higher (75.5%) (13) . In contrast, only 28.8% of placebo-treated patients had any improvement in % predicted FVC at 12 months, and 37.5% had any improvement in % predicted FVC at 24 months ( Supplementary Figures 2 and 3) . Table 1 for definitions. † The reference group is the placebo arm; therefore, these time trends represent the trends observed in the placebo arm. From 3 to 12 months, there was a significant decline in % predicted FVC in the placebo arm (estimated effect 20.49). ‡ Represents estimate for baseline differences in % predicted FVC by treatment arm. § These time trends represent trends observed in the MMF arm compared with those observed in the placebo arm. From 3 to 12 months, there was a significant improvement in % predicted FVC in the MMF arm compared with the placebo arm (estimated effect 0.68).
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The joint model also revealed that patients with a higher % predicted FVC at baseline had improved % predicted FVC over 24 months ( Table 2 ). The absolute change in % predicted FVC (unadjusted) over 24 months by treatment arm appears in Supplementary Table 1A (http:// onlinelibrary.wiley.com/doi/10.1002/art.40114/abstract).
Association of MMF treatment with improved course of DLCO. After controlling for baseline % predicted DLCO and baseline whole lung QILD score, treatment with MMF was associated with improved % predicted DLCO over 24 months (P , 0.0001) (Figure 2) . From 3 to 12 months, patients in the MMF arm experienced significant improvement in % predicted DLCO compared with those in the placebo arm (P 5 0.0063) (Figure 2 ), while patients in the placebo arm experienced significant decline in % predicted DLCO (P 5 0.0060) (Figure 2) . From 12 to 21 months (P 5 0.38) and from 21 to 24 months (P 5 0.99), there was no significant difference in % predicted DLCO between groups (Figure 2) . While statistically significant, the improvement in % predicted DLCO in the MMF arm relative to the placebo arm is of uncertain clinical significance.
The joint model also revealed that baseline % predicted DLCO (estimated effect 0.95; standard error 0.03; P , 0.0001) and baseline whole lung QILD score (estimated effect 0.08; standard error 0.03; P 5 0.0077) were independently associated with % predicted DLCO over 24 months (see Supplementary Association of MMF treatment with improved course of MRSS. In all patients (those with diffuse cutaneous SSc and those with limited cutaneous SSc combined), after adjustment for baseline MRSS, treatment with MMF was associated with improved MRSS over 24 months (P , 0.0001). From 3 to 12 months, patients in the MMF arm experienced a significant improvement (decrease) in the MRSS compared with those in the placebo arm (P 5 0.0018) (Figure 3 ). There was continued improvement in the MRSS from 12 to 21 months and from 21 to 24 months in the MMF arm. Patients in the placebo arm experienced an increase (worsening) in the MRSS from 3 to 12 months, followed by a decline in the MRSS from 12 to 21 months and from 21 to 24 months. Both treatment arms had similar rates of improvement in the MRSS from 12 to 21 months (P 5 0.95) and from 21 to 24 months (P 5 0.90) (Figure 3 ) (see Supplementary Table 3 , http://onlinelibrary. wiley.com/doi/10.1002/art.40114/abstract).
MMF was associated with a stronger treatment effect on the MRSS in patients with diffuse cutaneous disease (41 in the MMF arm and 45 in the placebo arm) than in all patients combined. From 3 to 12 months, the MRSS improved (declined) at a faster rate in the MMF arm Association of MMF treatment with improved course of TDI. After adjustment for baseline BDI, treatment with MMF was associated with improvement in Figure 2 . Course of the % predicted diffusing capacity for carbon monoxide (DLCO) from 3 to 24 months in Scleroderma Lung Study (SLS) II patients assigned to receive mycophenolate mofetil versus SLS I patients assigned to receive placebo, using joint model analysis. Values are the mean (numbers of patients at time points are shown for each group). The test of the overall treatment group effect was significant at P , 0.0001. Prespecified covariates for this model included baseline % predicted DLCO and baseline whole lung quantitative interstitial lung disease score. The dotted line represents the mean baseline value for the entire cohort. Figure 3 . Course of the modified Rodnan skin thickness score from 3 to 24 months in Scleroderma Lung Study (SLS) II patients assigned to receive mycophenolate mofetil versus SLS I patients assigned to receive placebo, using joint model analysis. Values are the mean (numbers of patients at time points are shown for each group). The test of the overall treatment group effect was significant at P , 0.0001. The dotted line represents the mean baseline value for the entire cohort. dyspnea compared with placebo as measured by the TDI (P 5 0.0112). From 3 to 12 months, patients in the MMF arm experienced a trend toward improvement in dyspnea compared with those in the placebo arm (P 5 0.0906) (Figure 4) . The observed improvement in the TDI in the MMF arm exceeded the minimal clinically important difference in the TDI for SSc-related ILD (23) . The TDI progressively worsened in the placebo arm during the first 12 months, but during the second year trended toward progressive improvement relative to the change during the first year of the study (see Supplementary Table 5 , http://onlinelibrary.wiley.com/doi/10.1002/art.40114/abstract). The absolute change in the TDI (unadjusted) over 24 months by treatment arm appears in Supplementary  Table 1E (http://onlinelibrary.wiley.com/doi/10.1002/art. 40114/abstract).
Safety analysis. In terms of predefined AEs that would warrant clinical intervention and a change in therapy, leukopenia (4 AEs in the MMF arm and none in the placebo arm), neutropenia (3 AEs in the MMF arm and none in the placebo arm), anemia (8 AEs in the MMF arm and 1 in the placebo arm), and pneumonia (5 AEs in the MMF arm and 1 in the placebo arm) occurred in more MMF-treated patients in SLS II than placebo-treated patients in SLS I (Table 3) . However, SAEs were experienced by more placebo-treated patients in SLS I (n 5 38) than MMF-treated patients in SLS II (n 5 27). Seven of the SAEs occurring in the placebo arm were judged by the Morbidity and Mortality Committee to be related to treatment, compared with 3 of the SAEs in the MMF arm. Numbers of deaths in the 2 groups were similar (5 in the MMF arm and 6 in the placebo arm).
DISCUSSION
The present report describes the first analysis comparing MMF with placebo for the treatment of SScrelated ILD, although using data from 2 independent studies with nearly identical designs and similar patient populations. The results reported herein demonstrate that treatment with MMF is associated with improvements in physiologic outcomes and dyspnea, as well as with reductions in the extent of cutaneous sclerosis, in comparison with placebo.
The observed treatment effects were greatest within the first 12 months of therapy and diminished with time. Possible explanations for this observation include the use of potential disease-modifying therapy in the placebo arm during months 12 to 24. As mentioned above, 12 patients received prednisone and 2 patients received CYC in the placebo arm during this period. Given the small number of patients receiving CYC and the lack of substantial evidence that prednisone prevents progression of SSc-related ILD, additional explanations for the loss of treatment effect after 12 months may relate to the natural history of SSc-related ILD. Steen and colleagues (24) demonstrated that the greatest decline in FVC occurs within the first year among patients with severe SSc-related ILD; therefore, it is plausible that lung function, as well as dyspnea as measured by the TDI, stabilized/improved in both groups after 12 months regardless of treatment. Similarly, the MRSS also improved in the placebo arm in the second year of the study, which again likely reflects the natural history of cutaneous sclerosis progression in SSc (25) . A survival bias may also contribute to the diminished MMF treatment effect in months 12 to 24, although our joint model analysis specifically adjusts for nonignorable missing data due to study dropout, treatment failure, or death.
Notably, compared with placebo, the MMF treatment effect persisted at 24 months in contrast to the CYC treatment effect observed in SLS I (3, 15) . In SLS I, less than half of the patients assigned to CYC had any improvement in % predicted FVC at 12 months (3), and by 24 months there was no difference in % predicted FVC between patients assigned to placebo and those assigned to CYC (15) . In contrast, the percentage of patients with any improvement in % predicted FVC at 24 months was substantially higher in patients receiving MMF (71.7%; nearly 3 times higher than in those assigned to placebo). Furthermore, even though % predicted FVC in the second year improved in both study arms, MMF still conferred an advantage at 24 months.
From the standpoint of safety and tolerability, MMF appears to be well tolerated. There were 8 predefined treatment failures in the placebo arm and none in the MMF arm over 24 months. Furthermore, 30 patients in the placebo arm experienced treatment failures/drug withdrawals compared with only 19 patients in the MMF arm during this time frame. As a reference point, there were 30 treatment failures/drug withdrawals in the CYC arm of SLS I and 34 treatment failures/drug withdrawals in the CYC arm of SLS II over 24 months.
The present analysis found that numerically more patients experienced AEs in the MMF arm than in the placebo arm; however, patients in the placebo arm experienced more SAEs. It is unclear why more SAEs occurred in the placebo arm; however, this may be related to progression of the SSc disease state in the absence of disease-modifying therapy, as most of the SAEs were not attributed to study drug in both groups. When compared with placebo, CYC use in SLS I was associated with more AEs, SAEs, and deaths (3). Taken together, these observations seem to suggest that MMF introduction may pose less serious risk to the patient.
The results of our analyses should be interpreted within the context of certain limitations. Namely, comparing cohorts from 2 different trials can introduce bias. Time period bias is one concern, as enrollment for SLS I concluded in 2004 and enrollment for SLS II concluded in 2012. However, this time difference is unlikely to contribute significantly to the phenotypic expression of SScrelated ILD in each cohort, as there were no new major therapeutic discoveries during this time period.
Of greater concern are potential differences in the baseline features of these 2 groups, which may affect progression of SSc-related ILD. Patients assigned to the placebo arm had greater radiographic extent of ILD and lower DLCO compared with patients assigned to the MMF arm. While we attempted to control for baseline ILD disease severity in our analyses (i.e., FVC, DLCO, whole lung QILD score), without a randomization process one cannot adequately control for those "unknown" variables that may be different in the 2 groups and that may affect the study outcome.
Reassuringly, the MMF and placebo groups appeared relatively similar in terms of their baseline features. Moreover, participants in SLS I and SLS II were recruited from similar academic centers. Nine of the 13 centers for recruitment in SLS I were used in SLS II. In addition, these 9 centers recruited the majority of patients for both SLS I and SLS II. The principal investigators from these centers were also similar for SLS I and SLS II, suggesting that practice management styles were likely consistent between the 2 trials.
VOLKMANN ET AL
Aside from the inherent limitations associated with comparing groups from different trials, our study also has important strengths. First, the number of patients is relatively large for an SSc-related ILD intervention study in both trials. Second, unlike many prior studies in this area, we did not evaluate an outcome measure at a single follow-up time point. Instead, we employed sophisticated statistical techniques to examine outcomes measured at multiple time points (i.e., FVC measured at 3-month intervals over 24 months), which likely results in a more clinically meaningful characterization of progression of SScrelated ILD. Third, our analysis adjusted for missing data due to dropouts, treatment failures, and deaths and thus represents a novel approach for dealing with nonignorable missing data in clinical trials.
To conclude, in patients with symptomatic SScrelated ILD, treatment with MMF is associated with improvements in the % predicted FVC, % predicted DLCO, TDI, and MRSS, compared with placebo using data from a historical study. The MMF treatment effect was greatest within the first 12 months but persisted throughout the 2-year trial. These findings support the use of MMF for the treatment of SSc-related ILD.
